Biophytis (EPA:ALBPS) | Finanzwire

Basculer en Français

10188	Companies
209712	Keywords
139865	Articles
111203	Press releases

Home
Companies
Biophytis

REGULATED PRESS RELEASE

published on 06/10/2024 at 08:18, 1 year 10 months ago

Biophytis announces filing of an IND application with the US FDA for its phase 2 study in obesity
Biophytis files IND application with US FDA for phase 2 obesity study with BIO101 (20-hydroxyecdysone) to assess muscle strength improvement in lower limbs and secondary endpoints like mobility and body composition

FDA Biophytis BIO101 IND Application Obesity Study
PRESS RELEASE

published on 06/10/2024 at 08:16, 1 year 10 months ago

Biophytis announces filing of an IND application with the US FDA for its phase 2 study in obesity
Biophytis submits IND application to US FDA for phase 2 obesity study with BIO101 (20-hydroxyecdysone). Study to assess muscle strength & body composition. Research led by Professor Marc-André Cornier

Biophytis BIO101 IND Application Obesity Study Professor Marc-André Cornier
BRIEF

published on 06/07/2024 at 08:28, 1 year 10 months ago

Biophytis Announces Combined General Meeting on June 24, 2024

Shareholders Biophytis General Meeting Voting Agenda
REGULATED PRESS RELEASE

published on 06/07/2024 at 08:23, 1 year 10 months ago

Combined General Meeting of June 24, 2024
Biophytis SA to hold Combined General Meeting (CGM) on June 24, 2024 in Paris. Shareholders encouraged to vote in advance via multiple methods. Details available on the company's website

Shareholders Voting Combined General Meeting Biophytis SA CGM
BRIEF

published on 06/07/2024 at 07:44, 1 year 10 months ago

Biophytis Combined General Meeting scheduled for June 24, 2024

Shareholders Biophytis Paris General Assembly Vote
PRESS RELEASE

published on 06/07/2024 at 07:39, 1 year 10 months ago

Combined General Meeting of June 24, 2024
Biophytis to hold Combined General Meeting (CGM) on June 24, 2024 at Sorbonne Université. Shareholders urged to vote in advance. Company specializes in age-related disease therapeutics

Shareholders Biophytis Therapeutics Combined General Meeting Age-related Diseases
BRIEF

published on 05/14/2024 at 07:05, 1 year 10 months ago

Biophytis Unveils Phase 2 OBA Clinical Study Design in Obesity

Biophytis Obesity Treatment Clinical Trial BIO101 OBA Clinical Study
PRESS RELEASE

published on 05/14/2024 at 07:00, 1 year 10 months ago

Biophytis announces the design of its phase 2 OBA clinical study in obesity
Biophytis announces the design of its phase 2 OBA clinical study in obesity with BIO101 (20-hydroxyecdysone), targeting muscle preservation in patients with obesity undergoing weight loss treatment with GLP-1 RAs

Biophytis BIO101 Muscle Preservation Obesity Phase 2 OBA Clinical Study
REGULATED PRESS RELEASE

published on 05/14/2024 at 07:00, 1 year 10 months ago

Biophytis announces the design of its phase 2 OBA clinical study in obesity
Biophytis announces the design of its phase 2 OBA clinical study in obesity with BIO101 (20-hydroxyecdysone), aiming to test efficacy and safety for muscle function in obese patients. Study to start mid-2024 with results expected in 2025

Biophytis BIO101 Obesity Phase 2 OBA Clinical Study Muscle Function
BRIEF

published on 04/29/2024 at 14:44, 1 year 11 months ago

Biophytis announces the deployment of its partnership strategy in the obesity sector

Strategic Partnerships Biophytis Pharmaceutical BIO101 Obesity

Accesswire

Published on 04/10/2026 at 17:55, 48 minutes ago

Nepra Foods Inc. Reports Preliminary Unaudited Fiscal 2026 Fourth Quarter Revenue of $1.85 Million, Demonstrating Continued Growth Momentum
Published on 04/10/2026 at 17:00, 1 hour 43 minutes ago

Arcus Appoints New Director and Officers
Published on 04/10/2026 at 14:45, 3 hours 58 minutes ago

Secure Blockchain Completes Acquisition of Agentic Solutions Limited, Launches Enterprise Agentic AI Platform
Published on 04/10/2026 at 14:30, 4 hours 13 minutes ago

Wi2Wi Corporation Announces Full Year 2025 Financial Results
Published on 04/10/2026 at 14:30, 4 hours 13 minutes ago

Unusual Machines Accelerates Motor Factory Output at Orlando Campus

View all ACCESSWIRE

EQS Group

Published on 04/10/2026 at 18:30, 12 minutes ago

AGM 2026 - Bossard Holding AG Press Release
Published on 04/10/2026 at 18:20, 23 minutes ago

Felicitysolar's Residential LiFePO4 Battery FLB48314TG1-H Wins 2026 Red Dot Design Award
Published on 04/10/2026 at 18:00, 43 minutes ago

Partners Group provides interim business update
Published on 04/10/2026 at 17:30, 1 hour 13 minutes ago

Swiss Re shareholders approve all proposals at AGM 2026
Published on 04/10/2026 at 16:30, 2 hours 13 minutes ago

O`KEY GROUP S.A. EGM APPROVES DELISTING OF GDRs FROM AIX

Les Echos

Published on 04/10/2026 at 18:35, 7 minutes ago

Disclosure of trading own shares
Published on 04/10/2026 at 18:26, 17 minutes ago

EURAZEO ANNOUNCES THE SUCCESS OF ITS INAUGURAL 500 MILLION EURO BOND ISSUE
Published on 04/10/2026 at 18:00, 43 minutes ago

Declaration of voting rights at the end of March 2026
Published on 04/10/2026 at 17:45, 58 minutes ago

Imerys-10-04-2026-implementation of the share buyback program
Published on 04/10/2026 at 10:00, 8 hours 43 minutes ago

Recticel Group’s acoustic materials used in NASA’s Artemis II-mission

View all LES ECHOS COMFI WIRE